| Literature DB >> 32699229 |
Hyeong Min Kim1, Kyu Hyung Park1, Se Joon Woo2.
Abstract
We investigated the full-field electroretinographic (ERG) parameters with visual function and prognosis in central retinal artery occlusion (CRAO), according to its severity. 110 affected eyes of CRAO patients were enrolled and compared with fellow uninvolved eyes (N = 110) and normal control eyes (N = 30). B/A ratio and photopic negative response amplitude (PhNR) resulted in statistically significant differences among the CRAO subgroups according to the severity of retinal ischemia. Amplitudes of PhNR indicating ganglion cell function showed a more marked decline in mild to severe ischemia than those of the B-wave. In terms of visual function and outcome, baseline visual acuity and visual field defects were correlated with B/A ratio only (both, P < .001), whereas improvements in visual acuity and visual field were correlated with B-wave amplitude in dark-adapted 3.0 (P = .004 and .006), B/A ratio (P = .023 and .008), and PhNR amplitude (P < .001 and .004). These three ERG parameters were found to be credible predictive factors of visual prognosis. In conclusion, B-wave amplitude in dark-adapted 3.0, B/A ratio, and PhNR amplitude changes in eyes with CRAO are associated with baseline features related to the severity of retinal ischemia, and these are correlated with visual function and prognosis.Entities:
Mesh:
Year: 2020 PMID: 32699229 PMCID: PMC7376222 DOI: 10.1038/s41598-020-68957-5
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Flow diagram showing the selection process of the enrolled eyes with central retinal artery occlusion. CRAO central retinal artery occlusion, ERG electroretinogram, FA fluorescein angiography, SD-OCT spectral domain optical coherence tomography.
Demographics and clinical characteristics of CRAO patients and comparisons based on the disease stage.
| Variables | All CRAO (N = 110) | Incomplete (N = 30) | Subtotal (N = 57) | Total (N = 23) | Incomplete vs Subtotal | Incomplete vs Total | Subtotal vs Total | |
|---|---|---|---|---|---|---|---|---|
| Mean age (year) | 60.8 ± 15.6 (17, 87) | 59.4 ± 14.8 (26, 82) | 61.2 ± 15.1 (17, 87) | 61.9 ± 18.2 (19, 82) | .806† | |||
| Male: Female | 67 : 43 | 22 : 8 | 33 : 24 | 12 : 11 | .235* | |||
| Standard treatment: Intra-arterial thrombolysis | 36 : 74 | 13 : 17 | 16 : 41 | 7 : 16 | .341* | |||
| Mean time from symptom onset to treatment (hour) | 25.1 ± 35.8 (1, 168) | 42.1 ± 51.8 (1, 168) | 19.1 ± 26.5 (1, 168) | 18.8 ± 24.4 (1, 100) | .999 | |||
| Mean follow-up period (month) | 15.7 ± 14.1 (1, 98) | 17.4 ± 15.2 (1, 74) | 14.1 ± 16.3 (1, 98) | 10.2 ± 8.9 (2, 38) | .264‡ | |||
| FA arm-to-retina time (sec) | 23.9 ± 8.9 (11, 55) | 21.0 ± 6.6 (11, 42) | 22.9 ± 7.5 (11, 47) | 29.8 ± 11.5 (13, 55) | .503 | |||
| Mean baseline BCVA | 2.17 ± 0.52 (20/90, NLP) | 1.64 ± 0.68 (20/90, HM) | 2.26 ± 0.22 (20/1,000, NLP) | 2.59 ± 0.23 (HM, NLP) | ||||
| Mean final BCVA | 1.84 ± 0.78 (20/18, NLP) | 0.97 ± 0.77 (20/18, HM) | 2.01 ± 0.48 (20/300, HM) | 2.52 ± 0.27 (FC, NLP) | ||||
| Visual acuity improvement¶ | 50/110 (46%) | 21/30 (70%) | 26/57 (46%) | 3/23 (13%) | ||||
| Mild : Severe VFDs | 43 : 67 | 26 : 4 | 16 : 41 | 1 : 22 | ||||
| Visual field improvement# | 25/54 (46%) | 15/20 (75%) | 10/27 (37%) | 0/7 (0%) | ||||
P values in boldface indicate statistical significance.
*Pearson’s Chi-Square test.
†One-way ANOVA for continuous parametric variables.
‡Kruskal–Wallis test and Mann–Whitney U test for continuous nonparametric variables.
¶Visual acuity improvement was evaluated as the improvement in final BCVA compared to baseline BCVA.
§Mild visual field defect includes peripheral constriction, paracentral scotoma, central and cecocentral scotoma, and severe visual field defect includes temporal island and no visual field.
#Visual field improvement was evaluated in only those that underwent at least two sequential visual field tests (N = 54).
CRAO central retinal artery occlusion, FA fluorescein angiography, logMAR logarithm of the minimal angle of resolution, FC finger count, HM hand motion, NLP no light perception, BCVA best-corrected visual acuity, VFD visual field defect.
Figure 2Representative figures of a patient diagnosed with incomplete CRAO in the right eye. Green line in the fundus photo indicates the scanning line of SD-OCT. (A) ERG pattern of the CRAO eye (right eye) and the fellow uninvolved eye (left eye). Slight decrease in the B-wave amplitude of the CRAO eye compared to the fellow uninvolved eye in the dark-adapted 3.0 ERG can be observed. Moreover, PhNR amplitude is depressed in the eye with CRAO compared to the fellow unaffected eye. (B–D) Fundus photo, FA and OCT images of the CRAO eye. FA arm-to-retina time was 19 s and OCT features inner retinal hyperreflectivity. Mild hypoperfusion was observed. (E, F) Plotted visual field at the initial and final visit. Notice that there was peripheral constriction only at the baseline and the visual field was enlarged at the final examination, suggesting visual field improvement.
Figure 3Representative figures of a patient diagnosed with subtotal CRAO in the right eye. Green line in the fundus photo indicates the SD-OCT scanning line. (A) ERG pattern of the CRAO eye (right eye) and the fellow uninvolved eye (left eye). B-wave amplitude in both dark-adapted and light-adapted responses and PhNR amplitudes decreased considerably in the subtotal CRAO, compared to the fellow uninvolved eye. (B–D) Fundus photo, FA and OCT images of the CRAO eye. FA arm-to-retina time was 24 s and OCT features moderate and diffuse inner retinal edema with small subretinal fluid. Severe hypoperfusion was observed. (E, F) Plotted visual field at the initial and final visit. Notice that there were nasal and temporal islands at the baseline and the visual field was constricted at the final examination, suggesting no visual field improvement.
Figure 4Representative figures of a patient diagnosed with total CRAO in the right eye. Green line in the fundus photo indicates the SD-OCT scanning line. (A) ERG pattern of the CRAO eye (right eye) and the fellow uninvolved eye (left eye). Compared to the ERG pattern in Fig. 3, more diminished responses in dark-adapted and light-adapted ERG, including PhNR amplitude, were observed in this case of total CRAO. (B–D) Fundus photo, FA and OCT images of the CRAO eye. FA arm-to-retina time was 39 s and OCT features severe diffuse inner retinal edema, subretinal fluid, and loss of retinal layers. Retinal perfusion was confined to the optic disc area. (E, F) Plotted visual field at the initial and final visit. Notice that there was small temporal island at the baseline and the visual field was constricted at the final examination, suggesting no visual field improvement.
Association of ERG parameters and CRAO eyes (based on the disease stage), Fellow uninvolved eyes, and Normal Controls.
| Parameters | All CRAO (N = 110) | Incomplete (N = 30) | Subtotal (N = 57) | Total (N = 23) | CRAO subgroups | Incomplete vs Subtotal | Incomplete vs Total | Subtotal vs Total | Fellow eyes (N = 110) | Involved vs Fellow | Control eyes (N = 30) | Control vs Fellow eyes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| B-wave amplitude (μV) | 135.09 ± 91.98 (5.3, 411.3) | 149.17 ± 85.11 (16.9, 344.1) | 125.18 ± 99.99 (13.0, 411.3) | 69.90 ± 56.98 (5.3, 220.0) | .394 | 199.56 ± 117.10 (13.1, 443.5) | 234.74 ± 98.65 (61.7, 409.7) | .080 | ||||
| Implicit time (ms) | 90.99 ± 16.48 (35.5, 133.1) | 91.26 ± 15.69 (66.0, 130.0) | 95.40 ± 19.05 (35.5, 138.1) | 97.47 ± 19.32 (42.5, 128.7) | .370† | .521 | .370 | .866 | 86.16 ± 16.92 (55.5, 135.6) | 80.17 ± 11.12 (60.0, 94.0) | .111 | |
| A-wave amplitude | 159.49 ± 67.72 (26.2, 334.3) | 160.87 ± 66.54 (52.3, 334.3) | 158.63 ± 63.75 (43.9, 327.3) | 143.76 ± 66.37 (26.2, 281.2) | .515† | .985 | .549 | .558 | 155.24 ± 72.99 (16.8, 336.7) | .887 | 150.02 ± 61.05 (81.2, 257.2) | .767 |
| A-wave implicit time | 24.66 ± 2.83 (18.0, 32.5) | 23.83 ± 2.28 (19.0, 28.0) | 24.75 ± 2.80 (18.0, 32.5) | 25.45 ± 3.22 (19.3, 32.0) | .066† | .229 | .056 | .148 | 22.62 ± 2.18 (16.3, 31.0) | 21.38 ± 2.76 (16.3, 26.5) | .094 | |
| B-wave amplitude | 244.33 ± 106.95 (17.3, 582.3) | 282.20 ± 103.93 (124.0, 529.0) | 248.26 ± 99.66 (107.0, 582.3) | 161.60 ± 66.96 (17.3, 260.3) | .200 | 329.10 ± 97.69 (85.7, 531.0) | 359.77 ± 89.67 (221.5, 527.5) | .198 | ||||
| B-wave implicit time | 50.73 ± 7.05 (34.0, 71.5) | 50.45 ± 4.61 (41.3, 63.0) | 50.95 ± 7.42 (34.0, 65.5) | 50.86 ± 7.04 (38.5, 71.5) | .937† | .932 | .969 | .998 | 46.48 ± 4.42 (35.5, 59.0) | 44.05 ± 7.05 (29.0, 53.6) | .159 | |
| B/A ratio | 1.59 ± 0.48 (0.64, 2.85) | 1.84 ± 0.45 (1.08, 2.77) | 1.62 ± 0.42 (0.83, 2.85) | 1.16 ± 0.35 (0.64, 2.23) | 2.52 ± 1.22 (1.20, 7.62) | 2.68 ± 0.99 (1.10, 5.27) | .602 | |||||
| Oscillatory potentials | 36.25 ± 21.43 (4.1, 92.3) | 35.49 ± 21.12 (9.2, 92.3) | 34.25 ± 23.14 (4.1, 90.1) | 24.32 ± 15.32 (4.3, 71.5) | .085‡ | .538 | .053 | .081 | 50.53 ± 28.95 (6.1, 144.1) | 56.97 ± 28.35 (21.1, 118.1) | .364 | |
| A-wave amplitude | 20.81 ± 10.38 (0.8, 54.9) | 24.15 ± 11.01 (6.2, 50.6) | 20.90 ± 10.50 (4.2, 54.9) | 15.28 ± 7.41 (0.8, 32.0) | .268 | 27.58 ± 12.25 (0.1, 67.7) | 29.56 ± 11.67 (16.0, 64.0) | .510 | ||||
| A-wave implicit time | 16.31 ± 3.13 (6.0, 27.5) | 15.65 ± 2.76 (6.0, 21.5) | 16.75 ± 3.30 (10.5, 27.5) | 16.89 ± 2.52 (12.0, 23.5) | .158† | .187 | .233 | .976 | 15.32 ± 1.84 (11.5, 25.5) | 15.01 ± 1.54 (13.0, 18.0) | .484 | |
| B-wave amplitude | 66.45 ± 37.20 (9.6, 176.8) | 77.31 ± 37.94 (23.8, 147.5) | 66.41 ± 35.40 (6.9, 176.8) | 44.74 ± 24.43 (12.0, 93.2) | .275 | 97.93 ± 38.70 (27.4, 225.2) | 100.40 ± 31.97 (50.3, 148.4) | .791 | ||||
| B-wave implicit time | 33.66 ± 3.27 (26.0, 47.0) | 31.61 ± 2.19 (26.0, 36.0) | 34.02 ± 3.35 (28.5, 47.0) | 34.56 ± 2.67 (29.0, 40.0) | .687 | 29.82 ± 2.51 (14.5, 41.0) | 29.16 ± 1.51 (25.5, 31.5) | .271 | ||||
− 25.76 ± 11.82 (− 57.2, − 4.8) | − 31.82 ± 13.58 (− 57.2, − 14.2) | − 17.31 ± 9.72 (− 32.9, − 8.4) | − 7.64 ± 3.21 (− 11.7, − 4.8) | − 47.27 ± 18.25 (− 76.4, − 19.2) | − 40.49 ± 12.41 (− 67.3, − 17.6) | .725 | ||||||
| Amplitude | 47.98 ± 24.69 (6.7, 113.5) | 54.47 ± 24.70 (16.3, 102.3) | 50.81 ± 23.71 (7.8, 113.5) | 33.41 ± 17.79 (6.7, 64.5) | .721 | 79.07 ± 27.80 (15.9, 156.3) | 74.44 ± 21.83 (36.5, 109.7) | .488 | ||||
| Implicit time | 32.45 ± 3.59 (24.5, 42.0) | 30.61 ± 2.82 (25.1, 35.8) | 33.20 ± 3.72 (24.5, 42.0) | 33.46 ± 3.48 (26.1, 40.0) | .934 | 28.09 ± 3.02 (23.1, 39.5) | 27.16 ± 3.02 (22.1, 37.5) | .118 | ||||
P values in boldface indicate statistical significance.
*P-values compared between each CRAO groups.
†One-way ANOVA and student t-test for continuous parametric variables.
‡Kruskal–Wallis test and Mann–Whitney U test for continuous nonparametric variables.
§P-values compared between CRAO involved eyes and fellow eyes. Paired t-test and Wilcoxon signed rank test for continuous parametric and nonparametric paired variables.
#P-values compared to fellow eye. Student t-test for continuous parametric variables and Mann–Whitney U test for continuous nonparametric variables.
ERG electroretinogram, CRAO central retinal artery occlusion.
Figure 5Bar graphs showing the association of ERG parameters and CRAO eyes (based on the disease stage), fellow uninvolved eyes, and control eyes. Detailed data are summarized in Table 2, and in this figure, we plotted bar graphs with relevant ERG parameters to visualize the tendency of ERG changes according to the severity of retinal ischemia.
Figure 6Relative ratio (% percentage) of ERG wave amplitude according to the severity of CRAO. First column describes the percentage ratio of incomplete CRAO compared to the fellow uninvolved eye; to figure out the initially damaged retinal cells and layers. In the early stage of retinal ischemia, PhNR amplitude decreases initially, followed by the dark-adapted 0.01 and light-adapted 3.0 ERG B-wave amplitude. Relatively the A-wave amplitude is preserved. This suggests that the retinal ganglion cells are the most vulnerable in retinal ischemia, and then the interneurons (bipolar cells), while the rods are the least vulnerable. Second and third columns describe the percentage ratio of subtotal and total CRAO compared to the incomplete CRAO. The results show that the PhNR amplitude is the most sensitive indicator for judging the severity of retinal ischemia.
Association of ERG parameters and clinical visual function & prognosis variables in eyes with CRAO.
| Parameters | Initial BCVA | Initial VFDs | Visual acuity improvement (N = 110) | Visual field improvement (N = 54)¶ | |||||
|---|---|---|---|---|---|---|---|---|---|
| BCVA improvement (N = 50) | No improvement (N = 60) | Visual field improvement (N = 25) | No improvement (N = 29) | ||||||
| Standard treatment : Intra-arterial thrombolysis | 17 : 33 | 19 : 41 | .795# | 7 : 18 | 7 : 22 | .805# | |||
| Dark-adapted 0.01 | B-wave amplitude (μV) | .636 | .274† | 131.45 ± 91.55 | 109.57 ± 92.13 | .174† | 180.81 ± 96.84 | 139.92 ± 92.96 | .120† |
| Implicit time (ms) | .597 | .661† | 91.41 ± 17.36 | 97.52 ± 18.70 | .055† | 87.50 ± 16.47 | 85.34 ± 15.37 | .620† | |
| Dark-adapted 3.0 | A-wave amplitude | .941 | .773† | 163.51 ± 61.19 | 149.79 ± 67.58 | .227† | 185.79 ± 73.36 | 170.84 ± 67.30 | .438† |
| A-wave implicit time | .676 | .593† | 24.41 ± 1.98 | 24.88 ± 3.35 | .310† | 24.03 ± 2.67 | 25.07 ± 2.83 | .172† | |
| B-wave amplitude | .339 | .093† | 333.98 ± 67.81 | 217.19 ± 73.85 | 342.92 ± 56.48 | 245.74 ± 65.30 | |||
| B-wave implicit time | .843 | .779† | 50.33 ± 5.55 | 51.19 ± 7.47 | .460† | 50.28 ± 5.58 | 50.62 ± 7.44 | .850† | |
| B/A ratio | 1.68 ± 0.31 | 1.43 ± 0.21 | 1.83 ± 0.23 | 1.46 ± 0.19 | |||||
Dark-adapted 3.0 Oscillatory potentials | .691 | .641‡ | 35.34 ± 21.53 | 30.01 ± 21.20 | .154‡ | 44.43 ± 23.77 | 40.67 ± 21.45 | .544‡ | |
Light-adapted 3.0 | A-wave amplitude | .250 | .289† | 21.99 ± 11.91 | 19.33 ± 8.99 | .156† | 10.79 ± 2.15 | 11.43 ± 2.12 | .107† |
| A-wave implicit time | .812 | .952† | 16.41 ± 2.48 | 16.56 ± 3.43 | .767† | 15.71 ± 2.20 | 14.93 ± 2.60 | .244† | |
| B-wave amplitude | .344 | .087† | 69.34 ± 34.52 | 63.28 ± 38.41 | .330† | 83.84 ± 37.68 | 63.96 ± 36.84 | ||
| B-wave implicit time | .597 | .084† | 32.71 ± 2.92 | 34.17 ± 3.19 | 32.42 ± 2.28 | 33.70 ± 3.16 | .090† | ||
| Photopic negative response | .071 | .375† | − 22.14 ± 4.25 | − 13.72 ± 3.97 | − 21.56 ± 5.52 | − 15.33 ± 4.18 | |||
Light-adapted 3.0 flicker | Amplitude | .700 | .222 | 52.55 ± 23.92 | 44.22 ± 23.57 | .052† | 56.24 ± 23.98 | 46.79 ± 25.57 | .129† |
| Implicit time | .607 | .326 | 31.69 ± 3.80 | 33.31 ± 3.32 | 31.07 ± 2.42 | 33.21 ± 4.03 | |||
P values in boldface indicate statistical significance.
*Correlation analysis.
†One-way ANOVA and student t-test for continuous parametric variables.
‡Kruskal–Wallis test and Mann–Whitney U test for continuous nonparametric variables.
¶Visual field improvement was evaluated in only those underwent at least two sequential visual field tests (N = 54).
#Pearson’s Chi-Square Test.
ERG electroretinogram, CRAO central retinal artery occlusion, BCVA best-corrected visual acuity, VFD visual field defect.
Figure 7Bar graphs showing the association of ERG parameters and visual prognosis in CRAO eyes. Detailed data is summarized in Table 3, and in this figure, we plotted bar graphs with relevant ERG parameters to visualize the tendency of ERG changes according to the visual acuity and field defect improvement.
Figure 8ROC curves presenting the predictive accuracy of ERG parameters, B-wave amplitude in dark-adapted 3.0 ERG (Red), B/A ratio (Green), and PhNR (Blue), in visual acuity and visual field improvement. Combinations of three parameters were also elicited with higher AUCs and significance (not described in this ROC curves figure). In VA improvement, the data is as follows: B-wave amplitude (AUC 0.630, P = .020); B/A ratio (AUC 0.586, P = .120); PhNR (AUC 0.574, P = .181); Combination of three parameters (AUC 0.646, P = .009). In VFD improvement, the data is as follows: B-wave amplitude (AUC 0.733, P = .004); B/A ratio (AUC 0.699, P = .013); PhNR (AUC 0.652, P = .058); Combination of three parameters (AUC 0.759, P = .001).